- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Fabry disease
- Meeting Date: July 2025
- Public Summary Document (PSD) July 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) July 2025 PBAC Meeting - (Word)
Pegunigalsidase Alfa – July 2025
Pegunigalsidase Alfa; Solution for I.V. injection 20 mg in 10 mL vial; Elfabrio®
Last updated
9 July 2025